Goedert James J, Chen Bingshu E, Preiss Liliana, Aledort Louis M, Rosenberg Philip S
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA.
Am J Epidemiol. 2007 Jun 15;165(12):1443-53. doi: 10.1093/aje/kwm030. Epub 2007 Mar 22.
Hepatitis C virus (HCV) is a blood-borne infection readily transmitted by transfusion. Persons with hemophilia were at very high risk of acquiring HCV, but the chronology and correlates of HCV incidence in the US hemophilia population remain unknown. The authors used multiple data sources and new statistical methods to reconstruct HCV incidence in White males with hemophilia A from 1940 through 1990. HCV incidence was approximately 1%/year until 1950 but 2-3%/year by 1955. With mild hemophilia, HCV incidence increased in the 1960s, reaching a plateau of approximately 8%/year from 1969 to 1980. With moderate and severe hemophilia, HCV incidence increased steeply to peaks of 11.7%/year in 1970 and 17.2%/year in 1968, respectively. Overall, HCV incidence declined after 1970, steeply after 1984, to nearly zero by 1990. With improving and increasing use of plasma derivatives, the size of the hemophilia population increased 86% during these 50 years. Study results imply that these life-saving treatments also carried an increasing risk of HCV, particularly before clotting factor concentrates were licensed in the 1970s. They also suggest that multiple synergistic interventions since 1970, particularly donor deferral, screening for hepatitis B and human immunodeficiency virus, and viral inactivation of clotting factor concentrates, were needed to reduce transfusion of HCV prior to its discovery.
丙型肝炎病毒(HCV)是一种通过输血容易传播的血源性感染病毒。血友病患者感染HCV的风险非常高,但美国血友病患者群体中HCV感染的时间顺序及相关因素仍不明确。作者使用多个数据源和新的统计方法,重建了1940年至1990年患有甲型血友病的白人男性的HCV感染率。1950年之前,HCV感染率约为每年1%,但到1955年时达到每年2%-3%。对于轻度血友病患者,HCV感染率在20世纪60年代有所上升,在1969年至1980年期间达到约每年8%的稳定水平。对于中度和重度血友病患者,HCV感染率分别在1970年急剧上升至每年11.7%的峰值以及在1968年升至每年17.2%的峰值。总体而言,1970年之后HCV感染率下降,1984年之后急剧下降,到1990年几乎为零。随着血浆衍生物使用的改善和增加,这50年间血友病患者群体规模增长了86%。研究结果表明,这些挽救生命的治疗方法也带来了越来越高的HCV感染风险,尤其是在20世纪70年代凝血因子浓缩物获得许可之前。研究结果还表明,自1970年以来需要采取多种协同干预措施,特别是推迟献血者献血、筛查乙型肝炎和人类免疫缺陷病毒,以及对凝血因子浓缩物进行病毒灭活,以减少在发现HCV之前的输血感染。